Hunter Immunology starts national lung disease vaccine trial
Scientists at Hunter Immunology have developed a treatment for Chronic Obstructive Pulmonary Disorder, or COPD, which is being trialled on up to 340 patients at major hospitals around the country.
Recruitment is now underway at 23 sites, including The Austin Hospital, The Alfred and the Royal Melbourne in Victoria, St Vincents Hospital and the Prince of Wales Hospitals in Sydney and both Royal Brisbane and Royal Perth Hospitals.
The drug HI 164OV is taken orally and works by stimulating the immune system to alleviate the flare ups commonly occurring in patients with moderate to severe disease.
Most read news
Organizations
Other news from the department research and development
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.